Oslo University Hospital Initiates a Groundbreaking ALS Study
Oslo University Hospital is excited to announce the commencement of a multicentre randomized phase 2 trial of ILB® in ALS, aimed at offering new hopes for those affected by this challenging disease. The trial is set to start in early 2026 and will involve a rigorous comparison of ILB® with Riluzole, which is currently the standard treatment for ALS.
Study Details and Objectives
This clinical trial will include 116 participants over a span of 12 months, with efforts dedicated to rigorously determining the efficacy of ILB®. The study consists of a six-month double-blind phase where patients will be assigned either ILB® or Riluzole. Following this, a six-month open-label period will allow all participants access to both treatments, enhancing their care options.
Role of Tikomed in the Study
Tikomed, a notable pharmaceutical company, will play a crucial role in supplying ILB for both phases of the trial, including necessary placebos for the randomized controlled trial (RCT). Their commitment to advancing treatment options for neurodegenerative conditions is essential as this study progresses.
Regulatory Approvals and Expectations
All required regulatory approvals have been secured, paving the way for patient enrollment expected to begin in the early part of 2026. Enthusiastic anticipation surrounds the results, which are projected to be available by the conclusion of 2028. This timeline reflects the hospital's dedication to thorough and ethical research practices.
About Tikomed
Tikomed is a private pharmaceutical firm located in Viken, Sweden. They are focused on revolutionary therapies for neurodegenerative conditions, with an emphasis on the drug candidate ILB®, a dextran sulphate that has shown promising results in small phase 2a studies targeting ALS. Their efforts signify a major leap forward in ALS treatment possibilities.
Understanding ALS
Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is a severe neurodegenerative disorder that affects roughly 250,000 to 300,000 individuals globally. Approximately 60,000 new cases arise each year. This condition leads to devastating motor function decline, crucial symptoms include difficulties in swallowing and breathing, severely affecting the quality of life of those diagnosed.
Contact Information for Further Inquiries
For additional information, please reach out to Tikomed's Chief Medical Officer, Dr. Björn Pilström. Their commitment to advancing medical knowledge and treatment options is unwavering.
Frequently Asked Questions
What is the main aim of the ILB® trial?
The trial aims to evaluate the effectiveness of ILB® compared to Riluzole, the current ALS treatment standard.
Who is overseeing the study?
The study is coordinated by Dr. Angelina Hatlø Maniaol, a senior consultant neurologist.
What is Tikomed's role in this trial?
Tikomed will supply ILB and placebos for the study, contributing crucial resources for the trial.
When are the results expected?
Results from the study are anticipated to be available by the end of 2028.
What is ALS?
ALS is a progressive neurodegenerative disease that leads to muscle weakness and eventual loss of voluntary movement.
